Dargistotug Biosimilar - Research Grade

Human

TIGIT

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Human TIGIT (4E1.2) In Vivo Antibody - Low Endotoxin (ICH1219), Anti-Mouse TIGIT (1G9) In Vivo Antibody - Low Endotoxin (ICH1220), Tiragolumab Biosimilar - Research Grade (ICH5078), Vibostolimab Biosimilar - Research Grade (ICH5159), Tamgiblimab Biosimilar - Research Grade (ICH5279), Belrestotug Biosimilar - Research Grade (ICH5384), Domvanalimab Biosimilar - Research Grade (ICH5486), Etigilimab Biosimilar - Research Grade (ICH5536), Lancastotug Biosimilar - Research Grade (ICH5623), Ociperlimab Biosimilar - Research Grade (ICH5722), Ralzapastotug Biosimilar - Research Grade (ICH5803), Renvistobart Biosimilar - Research Grade (ICH5816)

https://www.imgt.org/mAb-DB/

ICH3002

Q495A1

Blue ice

This product is a research-grade biosimilar of dargistotug, supplied as an unconjugated, non-therapeutic analog of the originator antibody built around its target, TIGIT. It is intended strictly for research use only and is not a clinical drug. Dargistotug is a fully human IgG1 (kappa) monoclonal antibody directed against the inhibitory immune checkpoint receptor TIGIT, developed as an immuno-oncology agent to relieve TIGIT-mediated suppression of T cells and NK cells. This biosimilar reproduces the antigen-binding specificity of the originator so that investigators can study TIGIT engagement, checkpoint blockade, and downstream immune effects in controlled in-vitro and functional settings without needing the proprietary clinical material. It is produced to research-grade specifications with low endotoxin (typically less than 1 EU/mg), and can be offered in bulk milligram-to-gram quantities to support assay development, screening cascades, and comparability work. As an unconjugated human IgG1 with a human target, it is well suited to binding, blocking, and effector-function studies and to serving as a reference or benchmark antibody alongside other anti-TIGIT reagents. It carries no clone designation, being defined instead by its originator-matched sequence and specificity. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on activated T cells, regulatory T cells, and NK cells. It binds the nectin-family ligands CD155 (PVR) and, with lower affinity, CD112, which are frequently upregulated on tumor cells and antigen-presenting cells. Engagement of TIGIT delivers inhibitory signals through its ITIM/ITT-like motifs and outcompetes the co-stimulatory receptor CD226 (DNAM-1) for the same ligands, dampening T-cell and NK-cell activation, proliferation, and cytokine output. TIGIT thereby contributes to immune exhaustion and tumor immune evasion. Blocking TIGIT is pursued to restore CD226-driven co-stimulation and enhance anti-tumor immunity, often in combination with PD-1/PD-L1 blockade, making it a prominent immune-checkpoint target in oncology research.

V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks